Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Finished Goods (2025)

Crinetics Pharmaceuticals (CRNX) has 1 years of Finished Goods data on record, last reported at $18000.0 in Q4 2025.

  • For Q4 2025, Finished Goods changed N/A year-over-year to $18000.0; the TTM value through Dec 2025 reached $18000.0, changed N/A, while the annual FY2025 figure was $18000.0, N/A changed from the prior year.
  • Finished Goods reached $18000.0 in Q4 2025 per CRNX's latest filing.
  • Across five years, Finished Goods topped out at $18000.0 in Q4 2025 and bottomed at $18000.0 in Q4 2025.